1.Clinical significance of monoclonal gammopathy with undetermined significance--review.
Journal of Experimental Hematology 2010;18(5):1365-1369
Monoclonal gammopathy with undetermined significance (MGUS) is the most common plasma cell disorder, MGUS is an asymptomatic premalignant disorder, which is markedly underdiagnosed in the general population. The risk frequency of progression to multiple myeloma or a closely related plasma cell disorder was developed at a rate of 1.5% per year, indicating that the condition is not entirely benign. The cumulative probability of progression is 10% at 10 years, 21% at 20 years, and 26% at 25 years. As compared with control populations, the progression rate of MGUS into multiple myeloma, Waldenstr m's macroglobulinemia, AL amyloidosis and lymphoma were increased by 25, 46, 8.4 and 2.4 times respectively. Numerous reports suggest an association of MGUS with a wide variety of other malignant and nonmalignant diseases. The determining highest risk factors of progression, delaying or preventing the progression of MGUS, targeting at the highest risk of progression and improving overall quality of life, all of them are the current hot topics to be explored and summarized in this review.
Humans
;
Multiple Myeloma
;
etiology
;
Paraproteinemias
;
etiology
;
Risk Factors
3.Multiple myeloma with pulmonary embolism: a case report.
Ke-jing YING ; Yong ZHOU ; Hao JIANG ; En-guo CHEN ; Pan ZHOU
Chinese Medical Journal 2006;119(17):1481-1484
6.Bilateral polychromatic crystalline keratopathy as the initial manifestation of IgG-lambda multiple myeloma.
Fong Yee FOO ; Christopher KHNG ; Li Wern VOON
Annals of the Academy of Medicine, Singapore 2013;42(2):93-94
Adult
;
Corneal Diseases
;
diagnosis
;
etiology
;
Humans
;
Male
;
Multiple Myeloma
;
complications
;
diagnosis
7.Research on mechanism underlying bone damage in myeloma--review.
Journal of Experimental Hematology 2007;15(6):1340-1344
Multiple myeloma (MM) is a B cell malignancy characterized by enhanced bone loss that commonly associated with diffuse osteopenia, focal lytic lesions, pathologic fractures, and bone pain. The key mechanism of bone damage in myeloma is the abnormal regulation in bone metastasis, with increased osteoclast function and decreased osteoblast activity. This article reviewed the factors implicated, such as receptor activator of nuclear factor-kappaB (RANK), receptor activator of nuclear factor-kappaB ligand (RANKL), osteoprotegerin (OPG), macrophage inflammatory protein-1alpha (MIP-1alpha), SDF-1 and Wnt pathway. Further understanding of the regulation system of bone homeostasis helps to offer possible targets for future therapy.
Bone Diseases
;
etiology
;
Bone and Bones
;
pathology
;
Humans
;
Multiple Myeloma
;
complications
;
pathology
;
Osteoblasts
;
pathology
;
Osteoclasts
;
pathology